Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IOVA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIovance raises 2026 revenue guidance to $350M–$370M, reports stronger real-world Amtagvi response rates
Filed July 2, 2026 · Period ending June 30, 2026 · ~1 min read
Key Changes
-
high
Full-year 2026 revenue guidance set at $350M–$370M, with Q2 2026 expected at $86M–$88M, reflecting ~45% YoY growth as Amtagvi and Proleukin sales scale.
Exhibit 99.1 view on EDGAR → -
high
Real-world Amtagvi response rate of 44% (18/41 patients) exceeds pivotal trial's 31.4%, with 52% response in patients with two or fewer prior therapies, supporting earlier treatment use.
Exhibit 99.1 view on EDGAR → -
high
Cash position of $319M as of March 31, 2026, with runway extending into 2028, incorporating revenue growth and August 2025 restructuring savings.
Exhibit 99.1 view on EDGAR → -
medium
Authorized treatment center network expanded to over 90 sites as of May 7, 2026, including first Canadian location in Toronto, enabling broader patient access.
Exhibit 99.1 view on EDGAR →
Summary
Iovance updated its investor presentation with 2026 financial guidance and commercial progress metrics. The company expects full-year revenue of $350M–$370M, with second-quarter revenue of $86M–$88M, representing approximately 45% year-over-year growth driven by Amtagvi (its approved TIL therapy for advanced melanoma) and Proleukin sales. The $319M cash position as of March 31, 2026, provides runway into 2028.
The most significant disclosure is real-world Amtagvi response data showing a 44% overall objective response rate across 41 patients, materially higher than the 31.4% rate in pivotal trials. Patients with two or fewer prior therapies achieved a 52% response rate, suggesting the therapy may perform better when used earlier in the treatment sequence.
This real-world evidence could accelerate adoption and support label expansion efforts. The company has expanded its authorized treatment center network to over 90 sites, including its first Canadian location, broadening the infrastructure needed to deliver the complex cell therapy. Retail holders should watch $86M for Q2 earnings to confirm the guidance range and $88M for updates on treatment center activation rates, which directly impact revenue potential.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Iovance updated its corporate presentation for use at healthcare conferences and with analysts and investors.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On June 30, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.
The company refreshed its standard corporate presentation materials used for investor and analyst communications. This is a routine disclosure of updated marketing materials with no specific business event or financial impact disclosed.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Cash position (3/31/26) $319M
The company disclosed a cash position of $319 million as of March 31, 2026, with an expected cash runway extending into 2028. The disclosure provides visibility into the company's ability to fund operations and clinical development programs through the near term.
Added in current filing · view on EDGAR →
>90 Treatment Centers as of 05 /07/26* ... *Includes center s in final stages of readiness or soon to be authorized.
The company reported having over 90 authorized treatment centers (ATCs) as of May 7, 2026, including centers in final stages of readiness or soon to be authorized. This includes the first Canada ATC in Toronto. The expansion of the ATC network is critical to commercial uptake, as Amtagvi requires specialized facilities for administration and patient monitoring during the treatment regimen.
Added in current filing · view on EDGAR → · paraphrased
44 % ORR (18/41) ... 52 % ORR (12/23) ... 33% ORR (6/18)
The company disclosed real-world objective response rates (ORR) for Amtagvi in previously treated advanced melanoma: 44% overall (18 of 41 patients), 52% in patients with two or fewer prior lines of therapy (12 of 23 patients), and 33% in patients with three or more prior lines (6 of 18 patients). These real-world data, sourced from a transplantation and cell therapy conference presentation, show higher response rates than the 31.4% ORR observed in the pivotal clinical trials, particularly in earlier treatment lines, which may support broader adoption and earlier use in the treatment paradigm.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 7, 2026 · How we verify